JP2023516936A5 - - Google Patents
Info
- Publication number
- JP2023516936A5 JP2023516936A5 JP2022551318A JP2022551318A JP2023516936A5 JP 2023516936 A5 JP2023516936 A5 JP 2023516936A5 JP 2022551318 A JP2022551318 A JP 2022551318A JP 2022551318 A JP2022551318 A JP 2022551318A JP 2023516936 A5 JP2023516936 A5 JP 2023516936A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pvrig
- cancer
- tigit
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010174835 | 2020-03-13 | ||
| CN202010174835.4 | 2020-03-13 | ||
| PCT/CN2021/080470 WO2021180205A1 (zh) | 2020-03-13 | 2021-03-12 | Pvrig结合蛋白及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516936A JP2023516936A (ja) | 2023-04-21 |
| JP2023516936A5 true JP2023516936A5 (https=) | 2024-04-26 |
| JP7705873B2 JP7705873B2 (ja) | 2025-07-10 |
Family
ID=77672140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551318A Active JP7705873B2 (ja) | 2020-03-13 | 2021-03-12 | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4119162A4 (https=) |
| JP (1) | JP7705873B2 (https=) |
| KR (1) | KR20220154140A (https=) |
| CN (1) | CN115003333B (https=) |
| CA (1) | CA3170025A1 (https=) |
| TW (1) | TWI873311B (https=) |
| WO (1) | WO2021180205A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4403573A4 (en) * | 2021-09-15 | 2024-12-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY |
| WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
| CN115819582A (zh) * | 2021-12-24 | 2023-03-21 | 合肥天港免疫药物有限公司 | Pvrig的抗体或其抗原结合片段及其应用 |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| CN119487079A (zh) * | 2022-06-08 | 2025-02-18 | 山东先声生物制药有限公司 | 一种pvrig/tigit双特异性抗体药物组合物及其用途 |
| WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
| CN120112553A (zh) * | 2022-08-10 | 2025-06-06 | 广州百济神州生物制药有限公司 | 抗pvrig抗体和使用方法 |
| CN117957254A (zh) * | 2022-08-31 | 2024-04-30 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
| WO2024098980A1 (en) * | 2022-11-10 | 2024-05-16 | Huahui Health Ltd. | Anti-cd112r antibodies and use thereof |
| KR20250156744A (ko) * | 2023-03-15 | 2025-11-03 | 상하이 맙젠 바이오텍 리미티드 | Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도 |
| TW202502812A (zh) * | 2023-06-06 | 2025-01-16 | 大陸商上海藥明生物技術有限公司 | 抗pvrig抗體及其用途 |
| TW202523352A (zh) * | 2023-09-20 | 2025-06-16 | 大陸商來凱醫藥科技（上海）有限公司 | 抗ｐｖｒｉｇ或ｔｉｇｉｔ的抗體、由其構建的雙特異性抗體、其製備方法和用途 |
| CN120025447A (zh) * | 2023-11-23 | 2025-05-23 | 广东菲鹏制药股份有限公司 | 抗人pvrig抗体及其应用 |
| CN120005023B (zh) * | 2023-12-22 | 2025-12-26 | 华润生物医药有限公司 | 抗pvrig抗体及其用途 |
| CN120230207A (zh) * | 2023-12-29 | 2025-07-01 | 百奥泰生物制药股份有限公司 | Pvrig结合蛋白、双特异性抗体及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| EP3119913B1 (en) | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| MD4733C1 (ro) | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3653221T5 (da) * | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| US10550173B2 (en) * | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
| CN108290936B (zh) | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| PE20181046A1 (es) | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| WO2017066714A1 (en) * | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
| IL317989A (en) * | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| JP7348072B2 (ja) * | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| JP7317272B2 (ja) | 2017-09-29 | 2023-07-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 |
| KR20210016448A (ko) * | 2018-06-01 | 2021-02-15 | 컴퓨젠 엘티디. | 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법 |
| US12462008B2 (en) | 2021-04-23 | 2025-11-04 | Beijing Boe Technology Development Co., Ltd. | Unlocking control method and device, electronic apparatus, and computer-readable storage medium |
-
2021
- 2021-03-12 CA CA3170025A patent/CA3170025A1/en active Pending
- 2021-03-12 EP EP21768888.6A patent/EP4119162A4/en active Pending
- 2021-03-12 CN CN202180010585.3A patent/CN115003333B/zh active Active
- 2021-03-12 KR KR1020227034534A patent/KR20220154140A/ko active Pending
- 2021-03-12 WO PCT/CN2021/080470 patent/WO2021180205A1/zh not_active Ceased
- 2021-03-12 JP JP2022551318A patent/JP7705873B2/ja active Active
- 2021-03-12 TW TW110108958A patent/TWI873311B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516936A5 (https=) | ||
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| BR112019025188A2 (pt) | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos | |
| JP2022523740A (ja) | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 | |
| CN110882385A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JP2023502585A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| BR112020013144A2 (pt) | Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer | |
| CN108778332B (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP5220315B2 (ja) | 抗ＥｐＣＡＭ免疫グロブリン | |
| CA3110276A1 (en) | Treatment of triple negative breast cancer with targeted tgf-b inhibition | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| BR112021010999A2 (pt) | Uso de anticorpo pd-l1 de articulação do complexo de proteína il-15 para tratamento de doenças tumorais | |
| CN111629731A (zh) | 治疗癌症的组合物和方法 | |
| WO2021160151A1 (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| CN113018429A (zh) | 治疗卵巢癌的药物组合 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| TW202028248A (zh) | 使用抗ｃｄ１２３免疫結合物之治療方法 | |
| CN120344271A (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| WO2023134787A2 (zh) | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 | |
| TWI619728B (zh) | Ｇｉｓｔ之治療 | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| CN120695174A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |